JP2005539012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005539012A5 JP2005539012A5 JP2004526255A JP2004526255A JP2005539012A5 JP 2005539012 A5 JP2005539012 A5 JP 2005539012A5 JP 2004526255 A JP2004526255 A JP 2004526255A JP 2004526255 A JP2004526255 A JP 2004526255A JP 2005539012 A5 JP2005539012 A5 JP 2005539012A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- composition
- compound
- disorder
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 11
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 230000003676 hair loss Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000010410 reperfusion Effects 0.000 claims description 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 229910052717 sulfur Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 102000001267 GSK3 Human genes 0.000 claims 2
- 108060006662 GSK3 Proteins 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000003900 neurotrophic factor Substances 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 150000002926 oxygen Chemical class 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000019100 sperm motility Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 230000000982 vasogenic effect Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 0 *c1cc(*C2NNC3=C2C=C(*)C=C*3)nc(-c2c(C(F)(F)F)cccc2)n1 Chemical compound *c1cc(*C2NNC3=C2C=C(*)C=C*3)nc(-c2c(C(F)(F)F)cccc2)n1 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- 208000034799 Tauopathies Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- FLZGOKYWHQKDDA-UHFFFAOYSA-N CN(C)CCCc1cc(Nc2n[nH]c3c2C=CCN3C)nc(-c2ccccc2C(F)(F)F)n1 Chemical compound CN(C)CCCc1cc(Nc2n[nH]c3c2C=CCN3C)nc(-c2ccccc2C(F)(F)F)n1 FLZGOKYWHQKDDA-UHFFFAOYSA-N 0.000 description 1
- GOXYECCEIJZLDT-UHFFFAOYSA-N CN(C)CCNCCCc1cc(Nc2n[nH]c3c2cccn3)nc(-c2ccccc2C(F)(F)F)n1 Chemical compound CN(C)CCNCCCc1cc(Nc2n[nH]c3c2cccn3)nc(-c2ccccc2C(F)(F)F)n1 GOXYECCEIJZLDT-UHFFFAOYSA-N 0.000 description 1
- AQHAJNPKECDVLW-UHFFFAOYSA-N CN(CCCc1cc(Nc2n[nH]c3ncccc23)nc(-c2ccccc2C(F)(F)F)n1)CCN1CCOCC1 Chemical compound CN(CCCc1cc(Nc2n[nH]c3ncccc23)nc(-c2ccccc2C(F)(F)F)n1)CCN1CCOCC1 AQHAJNPKECDVLW-UHFFFAOYSA-N 0.000 description 1
- VXUZPNCRQMAOSN-UHFFFAOYSA-N CNCCCc1cc(Nc2n[nH]c3ncccc23)nc(-c2ccccc2C(F)(F)F)n1 Chemical compound CNCCCc1cc(Nc2n[nH]c3ncccc23)nc(-c2ccccc2C(F)(F)F)n1 VXUZPNCRQMAOSN-UHFFFAOYSA-N 0.000 description 1
- WRVWHILNJVMKCM-UHFFFAOYSA-N Cc1cc(Nc(c2c3)n[nH]c2ccc3F)nc(-c2ccccc2C(F)(F)F)n1 Chemical compound Cc1cc(Nc(c2c3)n[nH]c2ccc3F)nc(-c2ccccc2C(F)(F)F)n1 WRVWHILNJVMKCM-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- AIVIDAHSSPJVRI-UHFFFAOYSA-N FC(c(cccc1)c1-c1nc(C2CC2)cc(NC2=NNC3N=CC=CC23)n1)(F)F Chemical compound FC(c(cccc1)c1-c1nc(C2CC2)cc(NC2=NNC3N=CC=CC23)n1)(F)F AIVIDAHSSPJVRI-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- KIAZTGTVDUSYMD-UHFFFAOYSA-N OCCNCCCc1cc(Nc2n[nH]c3ncccc23)nc(-c2ccccc2C(F)(F)F)n1 Chemical compound OCCNCCCc1cc(Nc2n[nH]c3ncccc23)nc(-c2ccccc2C(F)(F)F)n1 KIAZTGTVDUSYMD-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40096702P | 2002-08-02 | 2002-08-02 | |
| US60/400,967 | 2002-08-02 | ||
| PCT/US2003/023950 WO2004013140A1 (en) | 2002-08-02 | 2003-07-31 | Pyrazole compositions useful as inhibitors of gsk-3 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006188629A Division JP2006273872A (ja) | 2002-08-02 | 2006-07-07 | Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物 |
| JP2010211448A Division JP2010280729A (ja) | 2002-08-02 | 2010-09-21 | Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005539012A JP2005539012A (ja) | 2005-12-22 |
| JP2005539012A5 true JP2005539012A5 (https=) | 2006-08-24 |
| JP4733388B2 JP4733388B2 (ja) | 2011-07-27 |
Family
ID=31495907
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004526255A Expired - Fee Related JP4733388B2 (ja) | 2002-08-02 | 2003-07-31 | Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物 |
| JP2006188629A Withdrawn JP2006273872A (ja) | 2002-08-02 | 2006-07-07 | Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物 |
| JP2010211448A Pending JP2010280729A (ja) | 2002-08-02 | 2010-09-21 | Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006188629A Withdrawn JP2006273872A (ja) | 2002-08-02 | 2006-07-07 | Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物 |
| JP2010211448A Pending JP2010280729A (ja) | 2002-08-02 | 2010-09-21 | Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7491730B2 (https=) |
| EP (1) | EP1532145B1 (https=) |
| JP (3) | JP4733388B2 (https=) |
| KR (1) | KR20050032105A (https=) |
| CN (2) | CN1319968C (https=) |
| AR (1) | AR040773A1 (https=) |
| AT (1) | ATE339419T1 (https=) |
| AU (2) | AU2003257078B2 (https=) |
| BR (1) | BR0313176A (https=) |
| CA (1) | CA2494100C (https=) |
| CO (1) | CO5700772A2 (https=) |
| DE (1) | DE60308387T2 (https=) |
| DK (1) | DK1532145T3 (https=) |
| EA (1) | EA200500299A1 (https=) |
| EC (1) | ECSP055640A (https=) |
| ES (1) | ES2273043T3 (https=) |
| IL (1) | IL166620A (https=) |
| MX (1) | MXPA05001367A (https=) |
| NO (1) | NO20051100L (https=) |
| NZ (2) | NZ550883A (https=) |
| PL (1) | PL374967A1 (https=) |
| PT (1) | PT1532145E (https=) |
| TW (1) | TWI324157B (https=) |
| WO (1) | WO2004013140A1 (https=) |
| ZA (1) | ZA200501124B (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| NZ526472A (en) | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| AU2003218215A1 (en) | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| DK1532145T3 (da) | 2002-08-02 | 2007-01-15 | Vertex Pharma | Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3 |
| WO2004072029A2 (en) | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
| WO2006007864A1 (en) * | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
| EP1789413A1 (en) | 2004-09-13 | 2007-05-30 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2006034207A2 (en) * | 2004-09-17 | 2006-03-30 | Vanderbilt University | Use of gsk3 inhibitors in combination with radiation therapies |
| AU2006279376B2 (en) | 2005-08-18 | 2011-04-14 | Vertex Pharmaceuticals Incoporated | Pyrazine kinase inhibitors |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| EP1954277B1 (en) | 2005-11-03 | 2017-01-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| CN102532133A (zh) | 2006-01-17 | 2012-07-04 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| SI2089367T1 (sl) | 2006-10-31 | 2012-02-29 | Pfizer Prod Inc | Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev |
| MX2009004807A (es) * | 2006-11-02 | 2009-06-15 | Vertex Pharma | Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa. |
| NZ577768A (en) | 2006-12-19 | 2012-01-12 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
| AU2007338754A1 (en) | 2006-12-21 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| US8802638B1 (en) | 2007-01-25 | 2014-08-12 | University Of South Florida | Flavonoid treatment of glycogen synthase kinase-based disease |
| AU2008210455A1 (en) * | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| MX2009009590A (es) * | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
| MX2009009592A (es) | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopiridinas utiles como inhibidores de proteinas cinasas. |
| ATE526328T1 (de) | 2007-03-09 | 2011-10-15 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyrimidine |
| AU2008240313A1 (en) | 2007-04-13 | 2008-10-23 | Aj Park | Aminopyrimidines useful as kinase inhibitors |
| AU2008247592A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| JP5389786B2 (ja) | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害として有用なアミノピリミジン |
| JP5451602B2 (ja) * | 2007-06-08 | 2014-03-26 | アッヴィ・インコーポレイテッド | キナーゼ阻害薬としての５−ヘテロアリール置換インダゾール類 |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| CN101790532B (zh) * | 2007-07-31 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法 |
| KR20090031122A (ko) * | 2007-09-21 | 2009-03-25 | 주식회사 중외제약 | 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물 |
| NZ586662A (en) | 2007-12-19 | 2012-08-31 | Vertex Pharma | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS |
| WO2009145814A2 (en) * | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
| WO2009154697A2 (en) | 2008-05-28 | 2009-12-23 | Massachusetts Institute Of Technology | Disc-1 pathway activators in the control of neurogenesis |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2010098888A1 (en) * | 2009-02-27 | 2010-09-02 | Massachusetts Institute Of Technology | Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders |
| WO2010104307A2 (ko) * | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| RS57869B1 (sr) | 2009-06-17 | 2018-12-31 | Vertex Pharma | Inhibitori replikacije virusa gripa |
| WO2011059388A1 (en) * | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Oxazolo[4,5-c]pyridine substituted pyrazine |
| US8592485B2 (en) * | 2010-06-17 | 2013-11-26 | Healthpartners Research Foundation | Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders |
| KR20120063283A (ko) * | 2010-12-07 | 2012-06-15 | 제일약품주식회사 | 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| AU2011343642A1 (en) | 2010-12-16 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| EP2671885A1 (en) * | 2012-06-05 | 2013-12-11 | Ares Trading S.A. | Imidazo-oxadiazole and Imidazo-thiadiazole derivatives |
| US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
| LT2970890T (lt) | 2013-03-14 | 2020-07-10 | The Brigham And Women`S Hospital, Inc. | Kompozicijos ir būdai, skirti epitelinių kamieninių ląstelių padauginimui ir kultivavimui |
| HRP20181272T1 (hr) | 2013-11-13 | 2018-10-05 | Vertex Pharmaceuticals Incorporated | Postupci priprave inhibitora replikacije virusa influence |
| RS59144B1 (sr) | 2013-11-13 | 2019-09-30 | Vertex Pharma | Inhibitori replikacije virusa influence |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| KR101731624B1 (ko) | 2014-07-01 | 2017-05-04 | 광주과학기술원 | 세포 리프로그래밍 유도용 조성물 |
| WO2016037016A1 (en) | 2014-09-03 | 2016-03-10 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤 |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| CN108779437A (zh) | 2016-01-08 | 2018-11-09 | 麻省理工学院 | 分化的肠内分泌细胞和胰岛素产生细胞的制备 |
| CN107151235B (zh) * | 2016-03-04 | 2019-12-13 | 上海市计划生育科学研究所 | 噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途 |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| WO2020052648A1 (zh) * | 2018-09-14 | 2020-03-19 | 江苏恒瑞医药股份有限公司 | 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133081A (en) | 1964-05-12 | J-aminoindazole derivatives | ||
| US3935183A (en) | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
| BE754242A (fr) | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
| US3998951A (en) | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
| DE2458965C3 (de) | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
| MA18829A1 (fr) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
| DOP1981004033A (es) | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
| SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
| SE8102194L (sv) | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
| JPS58124773A (ja) * | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | ５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
| JPS59173249U (ja) | 1983-05-07 | 1984-11-19 | 日本碍子株式会社 | 避雷器素子を内蔵したオ−プンヒユ−ズカツトアウト |
| EP0136976A3 (de) | 1983-08-23 | 1985-05-15 | Ciba-Geigy Ag | Verwendung von Phenylpyrimidinen als Pflanzenregulatoren |
| DE3725638A1 (de) | 1987-08-03 | 1989-02-16 | Bayer Ag | Neue aryloxy (bzw. thio)aminopyrimidine |
| JPH0532662A (ja) | 1990-11-09 | 1993-02-09 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5597920A (en) | 1992-04-30 | 1997-01-28 | Neurogen Corporation | Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes |
| JPH0665237A (ja) | 1992-05-07 | 1994-03-08 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
| WO1995009851A1 (en) | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
| WO1996014843A2 (en) | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
| IL117659A (en) | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| CA2230896A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US6716575B2 (en) | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| JPH10130150A (ja) | 1996-09-05 | 1998-05-19 | Dainippon Pharmaceut Co Ltd | 酢酸アミド誘導体からなる医薬 |
| GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| US6251911B1 (en) | 1996-10-02 | 2001-06-26 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| WO1998016502A1 (en) | 1996-10-11 | 1998-04-23 | Warner-Lambert Company | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
| EP1033910A4 (en) | 1997-10-10 | 2004-11-24 | Cytovia Inc | DIPEPTIDE APOPTOSE INHIBITORS AND THEIR USE |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| JP2000026421A (ja) | 1998-01-29 | 2000-01-25 | Kumiai Chem Ind Co Ltd | ジアリ―ルスルフィド誘導体及び有害生物防除剤 |
| BR9908004A (pt) | 1998-02-17 | 2001-12-18 | Tularik Inc | Composto, composição e método para prevençãoou supressão de uma infecção viral |
| CN1297354A (zh) | 1998-03-16 | 2001-05-30 | 西托维亚公司 | 二肽卡斯帕酶抑制剂及其用途 |
| YU76100A (sh) | 1998-06-02 | 2003-12-31 | Osi Pharmaceuticals Inc. | Pirolo(2,3-d) pirimidin preparati i njihova primena |
| KR100581199B1 (ko) * | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| CA2339188A1 (en) | 1998-08-21 | 2000-03-02 | Dupont Pharmaceuticals Company | Isoxazolo¬4,5-d|pyrimidines as crf antagonists |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| KR100860295B1 (ko) | 1998-10-08 | 2008-09-25 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
| ATE284387T1 (de) * | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| HUP0105092A3 (en) | 1999-01-13 | 2003-12-29 | Warner Lambert Co | 1-heterocycle substituted diarylamines and medicaments containing them |
| WO2000059509A1 (en) | 1999-03-30 | 2000-10-12 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| WO2000078757A1 (en) | 1999-06-17 | 2000-12-28 | Shionogi Bioresearch Corp. | Inhibitors of il-12 production |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| MXPA02001565A (es) | 1999-08-13 | 2005-07-14 | Vertex Pharma | Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas. |
| WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| TR200201431T2 (tr) | 1999-11-30 | 2002-09-23 | Pfizer Products Inc. | İmünosupresanlar olarak faydalı 2,4-diaminopirimidin bileşikleri |
| KR100840727B1 (ko) | 1999-12-02 | 2008-06-23 | 오에스아이 파마슈티컬스, 인코포레이티드 | 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법 |
| MY125768A (en) | 1999-12-15 | 2006-08-30 | Bristol Myers Squibb Co | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6376489B1 (en) | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| HUP0202332A2 (en) | 2000-02-05 | 2002-10-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of erk |
| EP1257546A1 (en) | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitors |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| JP2004501083A (ja) * | 2000-04-18 | 2004-01-15 | アゴーロン・ファーマシューティカルズ・インコーポレイテッド | プロテインキナーゼを阻害するためのピラゾール |
| ATE394102T1 (de) | 2000-06-28 | 2008-05-15 | Astrazeneca Ab | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren |
| IL154016A0 (en) | 2000-08-31 | 2003-07-31 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ATE335737T1 (de) | 2000-09-15 | 2006-09-15 | Vertex Pharma | Isoxazole und ihre verwendung als erk-inhibitoren |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002024667A1 (en) | 2000-09-20 | 2002-03-28 | Merck Patent Gmbh | 4-amino-quinazolines |
| AU2002228922A1 (en) | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| DE10061863A1 (de) | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
| US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| EP1347972A1 (en) * | 2000-12-19 | 2003-10-01 | Smithkline Beecham Plc | Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors |
| NZ526472A (en) | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| EP1373257B9 (en) | 2001-03-29 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| MXPA03009378A (es) | 2001-04-13 | 2004-01-29 | Vertex Pharma | Inhibidores de cinasas c-jun n-terminales (jnk) y otras proteinas cinasas. |
| US20030096813A1 (en) * | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
| AU2002308748A1 (en) * | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| US6825190B2 (en) * | 2001-06-15 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| WO2003004492A1 (en) * | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| DE60236322D1 (de) * | 2001-12-07 | 2010-06-17 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| WO2003078423A1 (en) | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Compositions useful as inhibitors of protein kinases |
| AU2003218215A1 (en) | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
| DE60327999D1 (de) | 2002-03-15 | 2009-07-30 | Vertex Pharma | Azolylaminoazine als inhibitoren von proteinkinasen |
| EP1485100B1 (en) | 2002-03-15 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Azinylaminoazoles as inhibitors of protein kinases |
| US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
| AU2003237121A1 (en) * | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| CA2491895C (en) * | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| DK1532145T3 (da) * | 2002-08-02 | 2007-01-15 | Vertex Pharma | Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3 |
-
2003
- 2003-07-31 DK DK03767010T patent/DK1532145T3/da active
- 2003-07-31 KR KR1020057001908A patent/KR20050032105A/ko not_active Abandoned
- 2003-07-31 WO PCT/US2003/023950 patent/WO2004013140A1/en not_active Ceased
- 2003-07-31 AT AT03767010T patent/ATE339419T1/de active
- 2003-07-31 CA CA2494100A patent/CA2494100C/en not_active Expired - Fee Related
- 2003-07-31 ES ES03767010T patent/ES2273043T3/es not_active Expired - Lifetime
- 2003-07-31 NZ NZ550883A patent/NZ550883A/en unknown
- 2003-07-31 EP EP03767010A patent/EP1532145B1/en not_active Expired - Lifetime
- 2003-07-31 EA EA200500299A patent/EA200500299A1/ru unknown
- 2003-07-31 JP JP2004526255A patent/JP4733388B2/ja not_active Expired - Fee Related
- 2003-07-31 CN CNB038219859A patent/CN1319968C/zh not_active Expired - Fee Related
- 2003-07-31 AU AU2003257078A patent/AU2003257078B2/en not_active Ceased
- 2003-07-31 BR BR0313176-9A patent/BR0313176A/pt not_active IP Right Cessation
- 2003-07-31 CN CNA2007100961579A patent/CN101037438A/zh active Pending
- 2003-07-31 DE DE60308387T patent/DE60308387T2/de not_active Expired - Lifetime
- 2003-07-31 NZ NZ538426A patent/NZ538426A/en not_active IP Right Cessation
- 2003-07-31 PT PT03767010T patent/PT1532145E/pt unknown
- 2003-07-31 ZA ZA200501124A patent/ZA200501124B/en unknown
- 2003-07-31 PL PL03374967A patent/PL374967A1/xx not_active Application Discontinuation
- 2003-07-31 MX MXPA05001367A patent/MXPA05001367A/es active IP Right Grant
- 2003-08-01 AR AR20030102785A patent/AR040773A1/es unknown
- 2003-08-01 US US10/632,340 patent/US7491730B2/en not_active Expired - Fee Related
- 2003-08-01 TW TW092121162A patent/TWI324157B/zh not_active IP Right Cessation
-
2005
- 2005-02-01 IL IL166620A patent/IL166620A/en not_active IP Right Cessation
- 2005-02-25 CO CO05017965A patent/CO5700772A2/es not_active Application Discontinuation
- 2005-03-01 NO NO20051100A patent/NO20051100L/no not_active Application Discontinuation
- 2005-03-02 EC EC2005005640A patent/ECSP055640A/es unknown
-
2006
- 2006-07-07 JP JP2006188629A patent/JP2006273872A/ja not_active Withdrawn
-
2008
- 2008-12-18 US US12/338,129 patent/US7872129B2/en not_active Expired - Fee Related
-
2010
- 2010-07-01 AU AU2010202787A patent/AU2010202787A1/en not_active Abandoned
- 2010-09-21 JP JP2010211448A patent/JP2010280729A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005539012A5 (https=) | ||
| CA2494100A1 (en) | Pyrazole compositions useful as inhibitors of gsk-3 | |
| JP5710251B2 (ja) | 新規ヘテロ環化合物およびその使用 | |
| JP6283033B2 (ja) | ウイルス感染症およびさらなる疾患の処置のためのアシルアミノピリミジン誘導体 | |
| JP6675334B2 (ja) | 脊髄性筋萎縮症を処置するためのイミダゾ［１，２−ａ］ピラジン−１−イルベンズアミド化合物 | |
| EP2371830B1 (en) | Method for producing diamine derivative | |
| RU2003115490A (ru) | Амидные производные в качестве антагонистов nmda рецептора | |
| CA2472149A1 (en) | New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments | |
| WO2004005290A1 (de) | Substituierte imidazotriazine | |
| JP2017510595A5 (https=) | ||
| JP2014193912A (ja) | 新規ヘテロ環化合物およびその使用 | |
| ATE403428T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| EP4183449A1 (en) | Autophagy inducing compounds and uses thereof | |
| JP2022541772A (ja) | インターロイキンの調節におけるプロドラッグ | |
| WO2025011661A1 (zh) | 整合酶抑制类的制剂及其制备方法 | |
| WO2024050434A1 (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | |
| ES2402060T3 (es) | Derivado de quinazolina y producto farmacéutico | |
| RU2007128964A (ru) | Антагонисты рецепторов 5-ht7 | |
| CN111410667A (zh) | 新型(1,2,4)三唑并(1,5-a)吡啶基磷氧化物及其用途 | |
| WO2024050431A2 (en) | Tapinarof and analogs thereof for use in treating ahr mediated diseases | |
| WO2025019590A2 (en) | Proteolysis targeting chimeras for treating neurodegeneration | |
| HK40093291A (en) | Autophagy inducing compounds and uses thereof | |
| JP2000509392A (ja) | Ａｉｄｓの治療に有効なｈｉｖプロテアーゼ阻害剤 | |
| WO2025019604A2 (en) | Proteolysis targeting chimeras for treating neurodegeneration | |
| JP2024520758A (ja) | Ｔｔｂｋ１の阻害剤 |